Mariani

Mariana Oncology is a clinical-stage biotechnology company specializing in the development of next-generation radioligand therapies (RLTs) for cancer. The company's proprietary platform utilizes macrocyclic peptides to create precision-engineered radiopharmaceuticals that combine the high affinity of antibodies with the favorable pharmacokinetics of small molecules. Its lead candidate, MC-339, is an actinium-225-based radioligand therapy designed to treat small cell lung cancer by delivering alpha-emitting radiation directly to tumor cells. In May 2024, Mariana Oncology was acquired by Novartis for $1 billion upfront, with potential additional payments of up to $750 million, highlighting its leadership in the emerging radiopharmaceutical sector.